Unknown

Dataset Information

0

A clinical and radiological objective tumor response with somatostatin analogs (SSA) in well-differentiated neuroendocrine metastatic tumor of the ileum: a case report.

ABSTRACT: Somatostatin analogs (SSAs) are typically used to treat the symptoms caused by neuroendocrine tumors (NETs), but they are not used as the primary treatment to induce tumor shrinkage. We report a case of a 63-year-old woman with a symptomatic metastatic NET of the ileum. Complete symptomatic response was achieved after 1 month of treatment with SSAs. In addition, there was an objective response in the liver, with the disappearance of secondary lesions noted on computed tomography scan after 3 months of octreotide treatment. Our experience suggests that SSAs could be useful for downstaging and/or downsizing well-differentiated NETs, and they could allow surgery to be performed. Such presurgery therapy could be a promising tool in the management of patients with initially inoperable NETs.

SUBMITTER: De Divitiis C 

PROVIDER: S-EPMC4386800 | biostudies-other | 2015

REPOSITORIES: biostudies-other

Json Xml
altmetric image

Publications

A clinical and radiological objective tumor response with somatostatin analogs (SSA) in well-differentiated neuroendocrine metastatic tumor of the ileum: a case report.

De Divitiis Chiara C   von Arx Claudia C   Carbone Roberto R   Tatangelo Fabiana F   Di Girolamo Elena E   Romano Giovanni Maria GM   Ottaiano Alessandro A   de Lutio di Castelguidone Elisabetta E   Iaffaioli Rosario Vincenzo RV   Tafuto Salvatore S  

OncoTargets and therapy 20150331

Somatostatin analogs (SSAs) are typically used to treat the symptoms caused by neuroendocrine tumors (NETs), but they are not used as the primary treatment to induce tumor shrinkage. We report a case of a 63-year-old woman with a symptomatic metastatic NET of the ileum. Complete symptomatic response was achieved after 1 month of treatment with SSAs. In addition, there was an objective response in the liver, with the disappearance of secondary lesions noted on computed tomography scan after 3 mon  ...[more]

Similar Datasets

Unknown Somatostatin Analogs Treated Small Intestinal Neuroendocrine Tumor Patients Circulating MicroRNAs.
| S-EPMC4420277 | biostudies-other
Unknown Two well-differentiated pancreatic neuroendocrine tumor mouse models.
| S-EPMC7206057 | biostudies-literature
Unknown Antitumor effects of somatostatin analogs in neuroendocrine tumors.
| S-EPMC3380872 | biostudies-literature
Unknown Genomic characterization of a well-differentiated grade 3 pancreatic neuroendocrine tumor.
| S-EPMC6549554 | biostudies-literature
Unknown A pilot genome-wide association study shows genomic variants enriched in the non-tumor cells of patients with well-differentiated neuroendocrine tumors of the ileum.
| S-EPMC3221459 | biostudies-literature
Unknown Phase I Trial of Well-Differentiated Neuroendocrine Tumors (NETs) with Radiolabeled Somatostatin Antagonist <sup>177</sup>Lu-Satoreotide Tetraxetan.
| S-EPMC8382090 | biostudies-literature
Unknown Targeted therapy in advanced well-differentiated neuroendocrine tumors.
| S-EPMC3228104 | biostudies-literature
Unknown The expanding role of somatostatin analogs in the management of neuroendocrine tumors.
| S-EPMC3481148 | biostudies-literature
Unknown Site-Specific Genomic Alterations in a Well-Differentiated Pancreatic Neuroendocrine Tumor With High-Grade Progression.
| S-EPMC5884111 | biostudies-literature
Unknown Ribociclib and everolimus in well-differentiated foregut neuroendocrine tumors.
| S-EPMC8428776 | biostudies-literature